Friday, January 6, 2012

[Comment] Treatment of prostate cancer metastases: more than semantics

Prostate cancer is a unique disease that is characterised at advanced stages by a dominance of bone-forming metastases. Our understanding of bone metastasis with support from experimental findings has led investigators to target these metastases therapeutically, and the report by Matthew Smith and colleagues 1 in The Lancet is a result of these efforts.

Denosumab is an inhibitor of RANK ligand (RANKL), which is mechanistically implicated in, and clinically associated with, prostate cancer progression ...

Source: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61540-7/fulltext?rss=yes

fracking drosselmeyer drosselmeyer pacific standard time local time lsu alabama when is daylight savings 2011

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.